Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519346 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL6216931 | 0.90 | ALDH1A1 (0.49) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL28465542 | 0.89 | PRSS1 (0.48) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL20571668 | 0.87 | KDM4E (0.41) | KDM4EALDH1A1GAAKAT2BRAB9A | |
| SCHEMBL16155889 | 0.86 | KDM4E (0.54) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL31069432 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL1206785 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL29519371 | 0.80 | KAT2B (0.46) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL24320215 | 0.80 | PTGER4 (0.56) | KDM4EALDH1A1GAAPRSS1KAT2B | |
| SCHEMBL7183036 | 0.80 | ALDH1A1 (0.48) | KDM4EALDH1A1GAAPRSS1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023131333-A1 | BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131333-A1 | BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2023-07-13 | — | — | WO | disclosed |
| EP-3468966-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2017214367-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214367-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| CN-1305470-A | Amidine compounds | JAPAN TOBACCO INC (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | KDM4E 2441/4885ALDH1A1 1115/4885GAA 1301/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | KDM4E 171/4885ALDH1A1 4369/4885GAA 4640/4885 |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | KDM4E 171/4885ALDH1A1 4369/4885GAA 4640/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | KDM4E 171/4885ALDH1A1 4369/4885GAA 4640/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | KDM4E 171/4885ALDH1A1 4369/4885GAA 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.